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Supplemental Table 1 The ALL subtypes of the 129 patients for whom gene expression was performed included 40 with the TEL-AML1 gene fusion t(12;21), 33 hyperdiploid (>50 chromosomes), six with the E2A-PBX1 gene fusion t(1;19), five with the BCR-ABL gene fusion t(9;22) and three with the MLL-AF4 gene fusion t(4;11). The remaining 40 B-lineage ALLs were negative for all five of these genetic subtypes. White blood cell count at diagnosis (WBC), age at diagnosis and sex in patients defined as cross-resistant (n=29) or cross-sensitive (n=38) by the CR-score. Patients with VCRsensitive plus ASP-resistant ALL (VCR-S+ASP-R, n=42) or VCR-resistant ALL plus ASPsensitive (VCR-R+ASP-S, n=34), as defined by the VCR-ASP discordant resistance phenotype.
TEL-AML1 translocation and hyperdiploidy showed a trend of higher prevalence in younger children, but was not statistically significant in our population (P=0.1074, ANOVA). Sixteen of 34 (47%) ALLs that were VCR-resistant plus ASP-sensitive compared to only three of 42 (7%) that were VCR-sensitive plus ASP-resistant, had the t(12;21) translocation yielding the TEL-AML1 gene fusion (P=0.0001, Fisher's exact test). Fifteen of 34 (44%) ALLs that were VCR-resistant plus ASP-sensitive, compared to only four of 42 (10%) that were VCR-sensitive plus ASPresistant, were hyperdiploid (P=0.001, Fisher's exact test). All 19 TEL-AML1 positive and 19 hyperdiploid ALLs grouped together in one branch in the hierarchical clustering using the 200 probe sets discriminating VCR-ASP-discordant resistance (Supplemental Figure 6A ). Supplemental Table 3 : Cross-validation using gene expression scores for cross-resistance and VCR-ASP discordant resistance.
Spearman's rank correlation (rho) and P-value for top probe sets discriminating cross-resistance and vincristine-asparaginase (VCR-ASP) discordant resistance are listed. In each iteration, based on 10-fold cross-validation, genes were reselected (A) or were not reselected (B).
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Cross-resistance VCR-ASP discordance Cross-resistance VCR-ASP discordance Supplemental Table 4 : Transcription factor motifs over-represented in the set of genes over-expressed in cross-resistant versus cross-sensitive ALL.
The promoter region and the 5'UTR for specific sets of genes was used for Match™ to search the most recent TRANSFAC ® Professional 8.1 database (vertebrates) (http://www.biobase.de/) for common regulatory elements. We determined statistical overrepresentation of the common motifs compared to "all" (~20,000) human promoter sequences (UCSC hg17; CLOVER) (Matys et al., 2003) and additionally we used the promoter sequences of the "other" gene set as background.
For the 10 genes that were commonly over-expressed in cross-resistant ALL (2 of 12 were excluded, SLC4A1 because no reliable upstream region was found, and MUC4 because the expression levels were relatively low), we identified 41 common transcription factor binding sites within 1.5kb 5' of the transcription start site, and of those eight were significantly over-represented in these 10 genes compared to all human promoter sequences and to the promoter sequences of 34 genes that were under-expressed in cross-resistant ALL (P<0.05). For these eight factors, we found 14 probe sets on the array. Two of these factors that interact with one of the eight overrepresented binding motifs are expressed at a significantly different level in cross-resistant versus cross-sensitive ALL cells (ELF2, lower; IRF1 higher). Different isoforms of ELF2 are known to act as either an inhibitor or a transactivator and physically interact with the AML1 (RUNX1) domain (Cho, J, JBC, 2004) . IRF1 encodes interferon regulatory factor 1, a member of the interferon regulatory transcription factor (IRF) family. IRF1 functions as a transcription activator of interferons and interferon targets.
In addition, a transcription binding site for GATA3, a transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes, was identified in all 10 genes (although not over-represented compared to the human genome), and interestingly GATA3 was among the genes that were over-expressed in cross-resistant ALL (R/S ratio 3.38). The gene probe set, transcription factor name (TF), gene symbol (GS), Pearson correlation coefficient (R2) of the expression level with the CR-score, the R/S ratios comparing their expression in crossresistant (R) versus cross-sensitive (S) ALL, and the raw score and P-values from the TRANSFAC analysis are listed. 0.009 * P-value from over-representation compared to "all" ~20,000 human promoter sequences + P-value from over-representation compared to promoter sequences of "other" 34 under-expressed genes The promoter region and the 5'UTR for specific sets of genes was used for Match™ to search the most recent TRANSFAC ® Professional 8.1 database (vertebrates) (http://www.biobase.de/) for common regulatory elements. We determined statistical over-representation of the common motifs compared to "all" (~20,000) human promoter sequences (UCSC hg17; CLOVER) (Matys et al., 2003) and additionally we used the promoter sequences of the "other" gene set as background.
Supplemental
We found a total of 152 common transcription factor binding sites in the promoter regions of these 59 genes (3kb 5' of the transcription start site). Furthermore, we found significant overrepresentation of the same set of common transcription factor binding sites when sequences were compared against either "all" human promoter sequences or against the "other" 200 protein synthesis related genes. All these transcription factors are expressed in ALL cells except HEN1, M00264 V$STAF_02 Staf 3.59 0.023 0.017 * P-value from over-representation compared to "all" ~20,000 human promoter sequences + P-value from over-representation compared to promoter sequences of "other" 96 protein synthesis genes $ P-value <0.05 in the two VCR-ASP discordant resistance phenotypes Supplemental A. Hierarchical clustering of cross-resistant (red dots, n=29) and cross-sensitive (blue dots, n=38) patients using genes discriminating cross-resistance. Listed for each patient are gender (sex), age and white blood cell count at diagnosis (WBC) and ALL subtype colored in green TEL-AML1-positive and in blue hyperdiploid (HD) ALL. B. Hierarchical clustering of VCR-sensitive plus ASPresistant (blue dots, n=42) patients and VCR-resistant plus ASP-sensitive (orange dots, n=34) patients using genes discriminating VCR-ASP discordance resistance. C. Hierarchical clustering branch of patients using ALL subtype adjusted gene expression of VCR-ASP discriminating genes. Disease-free survival using the COALL/DCOG cohort (n=127) subdivided into equal groups (1/3) using the single PVAD resistance score (panel A). After stratification by PVAD, the worst group (n=41) was further divided into equal groups (1/2) by the VCR-ASP discordant resistance gene expression (VCR-ASP) score (panel B), revealing significant further discrimination by the VCR-ASP discordant resistance gene expression pattern. Shown is the disease-free survival in St.
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Jude patients (n=92), divided by the single PVAD resistance score defined by the COALL/DCOG cohort (panel C). After stratification by PDAV gene expression score, the worst group (n=19) was further divided into equal groups (1/2) by the multiple drug resistance (CR) gene expression score (panel D). After stratification by PVAD gene expression score, the worst group (n=19) was further sub-grouped (1/2) by the VCR-ASP discordant resistance gene expression score (panel D).
Patients whose ALL cells exhibit a gene expression pattern indicative of both worst crossresistance and worst VCR-ASP discordant resistance scores (i.e., the worst 25% of both CR-and VCR-ASP-scores are depicted in panel E. The 5-year treatment outcome of patients with both types of multiple-drug resistance (most unfavorable quartile for both CR and VCR-ASP) was 37%±13%, compared to 91%±9% in patients in the best quartile for both scores. 
Supplemental Discussion GLUT3
A gene significantly related to cross-resistance was SLC2A3 (GLUT3), and three additional probe sets represent the SLC2A3 (GLUT3) transporter were significantly correlated with the first component of the PCA (CR-score) and over-expressed in cross-resistant ALL (P=0.003, 0.01, 0.01; R/S ratio=1.4, 1.5, 1.7). SLC2A3 is a member of the solute carrier family 2, which functions as a facilitated glucose transporter and over-expression of SLC2A3 was previously detected in the murine erythroleukemia PC-V160 subline selected for vincristine resistance (which over-expresses ABCB1 (MDR1/PgP) and ABCC1 (MRP1). These cells exhibited an increased rate of facilitative glucose transport and glucose transport protein level in the plasma paralleled active VCR-efflux and increased VCR-resistance (Martell et al., 1997) .
GLUT3 up-regulation has been linked to malignant transformation and postulated to be a fundamental component of the carcinogenic process (Macheda et al., 2004) . Also, GLUT3 overexpression was detected in various cancers (e.g., lung, ovarian, gastric) but not in the corresponding normal tissues, and has been associated with tumor progression, worse outcome and metastasis (Younes et al., 1997a; Younes et al., 1997b) . It is conceivable that more efficient glucose metabolism serves as a general survival advantage (Burgman et al., 2001; Zelzer et al., 1998) .
